Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Stopped The single site that was deemed appropriate for this study was unable to enroll patients. Closed due to slow accrual.

Conditions

• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Myelodysplastic Syndrome Acute Myeloid Leukemia

Interventions

• DRUG: Nivolumab

Sponsor

SCRI Development Innovations, LLC

Collaborators

• [object Object]